Geode Capital Management, LLC Catalyst Pharmaceuticals, Inc. Transaction History

Geode Capital Management, LLC

$1.12 Trillion
Q2 2024

A detailed history of Geode Capital Management, LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 2,698,613 shares of CPRX stock, worth $53.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,698,613

Previous 2,508,152 7.59%

Holding current value

$53.5 Million

Previous $40 Million 4.56%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$14.68 - $16.92 $2.8 Million - $3.22 Million	190,461 Added 7.59%	2,698,613 $41.8 Million
Q1 2024 May 13, 2024	BUY	$13.18 - $17.11 $4.06 Million - $5.27 Million	307,927 Added 14.0%	2,508,152 $40 Million
Q4 2023 Feb 13, 2024	BUY	$11.78 - $17.29 $1.34 Million - $1.97 Million	113,858 Added 5.46%	2,200,225 $37 Million
Q3 2023 Nov 13, 2023	BUY	$11.69 - $15.02 $1.87 Million - $2.4 Million	159,952 Added 8.3%	2,086,367 $24.4 Million
Q2 2023 Aug 11, 2023	BUY	$11.5 - $18.08 $830,219 - $1.31 Million	72,193 Added 3.89%	1,926,415 $25.9 Million
Q1 2023 May 15, 2023	BUY	$14.34 - $21.05 $1.3 Million - $1.91 Million	90,832 Added 5.15%	1,854,222 $30.7 Million
Q4 2022 Feb 13, 2023	BUY	$12.25 - $19.5 $934,295 - $1.49 Million	76,269 Added 4.52%	1,763,390 $32.8 Million
Q3 2022 Nov 14, 2022	SELL	$7.06 - $15.52 $32,977 - $72,493	-4,671 Reduced 0.28%	1,687,121 $21.6 Million
Q2 2022 Aug 12, 2022	SELL	$6.23 - $8.57 $387,368 - $532,865	-62,178 Reduced 3.54%	1,691,792 $11.9 Million
Q1 2022 May 13, 2022	BUY	$5.31 - $8.31 $125,618 - $196,589	23,657 Added 1.37%	1,753,970 $14.5 Million
Q4 2021 Feb 11, 2022	SELL	$5.21 - $7.45 $868,314 - $1.24 Million	-166,663 Reduced 8.79%	1,730,313 $11.7 Million
Q3 2021 Nov 12, 2021	BUY	$4.85 - $6.04 $156,863 - $195,351	32,343 Added 1.73%	1,896,976 $10.1 Million
Q2 2021 Aug 13, 2021	BUY	$4.29 - $6.05 $419,424 - $591,496	97,768 Added 5.53%	1,864,633 $10.7 Million
Q1 2021 May 12, 2021	BUY	$3.45 - $4.69 $566,389 - $769,961	164,171 Added 10.24%	1,766,865 $8.15 Million
Q4 2020 Feb 12, 2021	BUY	$2.97 - $3.83 $162,358 - $209,370	54,666 Added 3.53%	1,602,694 $5.35 Million
Q3 2020 Nov 13, 2020	SELL	$2.97 - $5.08 $78,598 - $134,437	-26,464 Reduced 1.68%	1,548,028 $4.6 Million
Q2 2020 Aug 13, 2020	BUY	$3.48 - $5.05 $115,309 - $167,331	33,135 Added 2.15%	1,574,492 $7.27 Million
Q1 2020 May 14, 2020	BUY	$2.61 - $5.21 $96,663 - $192,957	37,036 Added 2.46%	1,541,357 $5.93 Million
Q4 2019 Feb 13, 2020	SELL	$3.67 - $5.7 $70,034 - $108,773	-19,083 Reduced 1.25%	1,504,321 $5.64 Million
Q3 2019 Nov 12, 2019	BUY	$3.89 - $7.43 $465,294 - $888,724	119,613 Added 8.52%	1,523,404 $8.09 Million
Q2 2019 Aug 14, 2019	BUY	$2.7 - $6.11 $694,896 - $1.57 Million	257,369 Added 22.45%	1,403,791 $5.39 Million
Q1 2019 May 14, 2019	BUY	$2.11 - $5.33 $174,399 - $440,545	82,654 Added 7.77%	1,146,422 $5.85 Million
Q4 2018 Feb 13, 2019	BUY	$1.92 - $3.62 $195,041 - $367,734	101,584 Added 10.56%	1,063,768 $2.04 Million
Q3 2018 Nov 13, 2018	BUY	$2.81 - $3.78 $4,540 - $6,108	1,616 Added 0.17%	962,184 $3.64 Million
Q2 2018 Aug 14, 2018	BUY	$2.26 - $3.84 $236,667 - $402,124	104,720 Added 12.24%	960,568 $3 Million
Q1 2018 May 15, 2018	BUY	$2.39 - $4.01 $262,510 - $440,446	109,837 Added 14.72%	855,848 $2.05 Million
Q4 2017 Feb 13, 2018	BUY	$2.51 - $4.4 $298,185 - $522,715	118,799 Added 18.94%	746,011 $2.92 Million
Q3 2017 Nov 14, 2017	BUY	$2.4 - $2.94 $32,071 - $39,287	13,363 Added 2.18%	627,212 $1.58 Million
Q2 2017 Aug 14, 2017	BUY	N/A	613,849	613,849 $1.69 Million

Others Institutions Holding CPRX

# of Institutions

285

Shares Held

96.6M

Call Options Held

29.2K

Put Options Held

20.5K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.04B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Catalyst Pharmaceuticals, Inc. Transaction History